EIF2A and acute lymphoblastic leukemia: This observation raises caution with regard to the utility of eIF2α phosphorylation as a biomarker for sensitivity to proteasome inhibitors in ALL cells, in distinction to what has been demonstrated for pancreas cancer cells [17].